Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.

Di Noia, V; Pimpinelli, F; Renna, D; Barberi, V; Pellini, R; Morrone, A; Giannarelli, D; Cognetti, F

Di Noia, V; Pimpinelli, F; Renna, D; Barberi, V; Pellini, R; Morrone, A; Giannarelli, D; Cognetti, F.

Afiliación

Di Noia V; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincenzo.dinoia@ifo.gov.it.
Pimpinelli F; Microbiology and Virology Unit, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Renna D; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Barberi V; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Rome, Italy.
Pellini R; Otolaryngology Head and Neck Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Morrone A; Scientific Direction, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Giannarelli D; Biostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cognetti F; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Rome, Italy.

Ann Oncol ; 33(3): 350-352, 2022 03.

Article en En | MEDLINE | ID: mdl-34861377

Asunto(s)

COVID-19; Neoplasias; Anticuerpos Antivirales; Vacuna BNT162; Humanos; Neoplasias/tratamiento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google